Significance of tumour markers in cancer of gall bladder

Sharada R. Kankonkar, S. V. Joshi, R. R. Deshpande

Medical Research Centre, Bombay Hospital Trust, Mumbai, India.
Tissue Typing Laboratory, Medical Research Centre, Bombay Hospital Trust, Mumbai, India.

DOI: 10.4236/oji.2013.31005                

Abstract

In India, GI tract cancer is one of the ten leading cancers. Among Indian males it stands second to oral cancer and in females, it shares the third place. Most common malignant disorder of GIT is seen in our country that of liver, bile, gall bladder, pancreas, bileduct and colorectal. Aim: To see the significance of tumour markers in gall bladder cancer. Materials and Methods:This study comprise 225 cases of GI tract cancers was carried for more than two years. Of these, 22 subjects had gallbladder cancer. Tumour markers viz. CA19-9, CEA and AFP were assayed pre and post-operative cases and their role in gallbladder cancer was evaluated. Results: It was observed that serum concentration of CA 19-9 increased with advancing stage, but the same is not true for AFP and CEA. Sensitivity of these markers AFP, CA 19-9 and CEA in the detection of gall bladder cancer was determined. CA 19-9 is the most sensitive of all the three tumour markers in the detection of gall bladder cancer. Conclusion: The combination of CA19-9 and CT (or US) is a reasonable, cost-effective, noninvasive approach to establishing the diagnosis of pancreatic, cholangitic, or biliary cancer in nonicteric patients.

Keywords

CA19-9; CEA; AFP; Gall Bladder Cancer

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Diehl, A.K. (1980) Epidemiology of gallbladder cancer: A synthesis of recent data. Journal of the National Cancer Institute, 65, 1209-1214.
[2]	Strom, B.L, Soloway, R.D, Rios-Dalenz, J.L. and Rodriguez-Martinez, H.A. (1995) Risk factors for gallbladder cancer. An international collaborative case-control study. Cancer, 76, 1747-1756. doi:10.1002/1097-0142(19951115)76:10<1747::AID-CNCR2820761011>3.0.CO;2-L
[3]	Yamaguchi, K., Chijiiwa, K., Ichimiya, H. and Sada, M. (1996) Gallbladder carcinoma in the era of laparoscopic cholecystectomy. Archives of Surgery, 131, 981-984. doi:10.1001/archsurg.1996.01430210079015
[4]	Marinus, J.P.G., van Kroonenburgh, H. and Pasmans L.M. (1991) A prospective analysis of 1518 laparoscopic cholecystectomies. The southern surgeons club. The New England Journal of Medicine, 324, 1073-1078. doi:10.1056/NEJM199104183241601
[5]	Satyanarayana, L. and Asthana, S. (2008) Life time risk for development of ten major cancers in India and its trends over the years 1982 to 2000. Indian Journal of Medical Sciences, 62, 35-44. doi:10.4103/0019-5359.39365
[6]	Pandey, M. and Shukla, V.K. (2003) Lifestyle, parity, menstrual and reproductive factors and risk of gallbladder cancer. European Journal of Cancer Prevention, 12, 269-272. doi:10.1097/00008469-200308000-00005
[7]	Pandey, M., Sood, B.P., Shukla, R.C. and Aryya, N.C. (2000) Carcinoma of the gallbladder: Role of sonography in diagnosis and staging. Journal of Clinical Ultrasound, 28, 227-232. doi:10.1002/(SICI)1097-0096(200006)28:5<227::AID-JCU4>3.0.CO;2-4
[8]	Kumar, A. and Aggarwal, S. (1994) Carcinoma of the gallbladder: CT findings in 50 cases. Abdominal Imaging, 19, 304-308. doi:10.1007/BF00198184
[9]	Sugaya, Y., Sugaya, H., Kuronuma, Y., Hisauchi, T. and Harada, T. (1989) A case of gallbladder carcinoma producing both alpha-fetoprotein (AFP) and carcinoembryonic antigen (CEA). Gastroenterologia Japonica, 24, 325-331.
[10]	Ono, T., Komatsu, M., Hoshino, T., Ishii, T., Fujii, T., Oshima, S., et al. (1996) Alpha-fetoprotein, carcinoembryonic antigen, and carbohydrate antigen 19-9-producing gallbladder cancer. Journal of Gastroenterology, 31, 742-746. doi:10.1007/BF02347628
[11]	Clarke, T., Matsuoka, L., Jabbour, N., Mateo, R., Genyk, Y., Selby, R., et al. (2007) Gallbladder mass with a carbohydrate antigen 19-9 level in the thousands: Malignant or benign pathology? Report of a Case Surgery Today, 37940, 342-344. doi:10.1007/s00595-006-3377-4
[12]	Khan, R.A., Wahab, S., Khan, M.A., Siddiqui, S. and Maheshwari, V. (2010) Advanced presentation of gallbladder cancer: Epidemioclinico pathological study to evaluate the risk factors and assess the outcome. Journal of the Pakistan Medical Association, 60, 217-219.
[13]	Canil, C.M. and Tannock, I.F. (2002) Doctor’s dilemma: Incorporating tumor markers into clinical decision-making. Seminars in Oncology, 29, 286-93. doi:10.1053/sonc.2002.32904
[14]	Sharma, R.G., Kumar, R., Jain, S., Jhajhria, S., Gupta, N., Gupta, S.K., et al. (2009) Distribution of malignant neoplasms reported at different pathology centers and hospitals in Jaipur, Rajasthan. Indian Journal of Cancer, 46, 323-330. doi:10.4103/0019-509X.55553
[15]	Shukla, V.K., Chauhan, V.S., Mishra, R.N. and Basu, S. (2008) Lifestyle, reproductive factors and risk of gallbladder cancer. Singapore Medical Journal, 49, 912-915.
[16]	Vij, U. and Baskaran, V. (2001) Value of serum CEA and AFP in the diagnosis and prognosis of carcinoma gallbladder. Tropical Gastroenterology, 22, 227-229.
[17]	Shukla, V.K., Gurubachan, Sharma, D., Dixit, V.K. and Usha (2006) Diagnostic value of serum CA242, CA 19-9, CA 15-3 and CA 125 in patients with carcinoma of the gallbladder. Tropical Gastroenterology, 27, 160-165.
[18]	Brockmann, J., Emparan, C., Hernandez, C.A., Sulkowski, U., Dietl, K.H., Menzel, J., et al. (2000) Gallbladder bile tumor marker quantification for detection of pancreatobiliary malignancies. Anticancer Research, 20, 4941-4947.
[19]	De Aretxabala, X., Riedeman, J.P., Roa, I., Wenzel, C., Inostroza, J., Burgos, L., et al. (1996) CA 19-9 and carcinoembryonic antigen in gallbladder cancer. Revista Médica de Chile, 124, 11-20.
[20]	Steinberg, W. (1990) The clinical utility of the CA 19-9 tumor-associated antigen. The American Journal of Gastroenterology, 85, 350-355.